Why is Assembly Biosciences stock surging today?

Assembly Biosciences saw its shares climb 4.9% in Tuesday’s after-hours session following the company’s announcement that it had exercised a contractual right to take part in a 40% allocation of U.S. development expenses and profits for its herpes simplex virus helicase-primase inhibitor program, which is being conducted alongside Gilead Sciences. The move came after Assembly Bio reviewed Gilead’s full development strategy and financial plan for the initiative, which focuses on two experimental assets — GS-1179 and GS-5366 — designed to treat recurrent genital herpes.

Through this opt-in choice, Assembly Bio sets itself up to capture a significant portion of any future U.S. commercial revenue, while Gilead continues to handle all clinical development and commercialization duties. Additionally, the company is still entitled to as much as $280 million in regulatory and commercial milestone payments, along with graduated royalties on sales outside the U.S. Reinforcing shareholder sentiment, Assembly Bio stated that its capital runway now stretches to 2029, aided partly by a $75 million collaboration extension payment from Gilead scheduled for Q4 2026.

On a day when the broader market gave little assistance — with the S&P 500 virtually flat, the Dow Jones slightly negative, and the Nasdaq also marginally down — the after-hours surge in ASMB was clearly company-specific. Gilead picked GS-1179, the lead herpes simplex virus candidate, for further development on the strength of Phase 1b results and its possible support for once-weekly oral dosing, which would differentiate it from current nucleoside analogue treatments.

All these factors — the opt-in decision, the extended cash runway, and an upcoming Phase 2 readout for GS-1179 — sent a strong message about progress to investors, lifting the stock to $37. That level surpassed the regular-session peak of $36.68 and moved closer to the 52-week high of $39.705.

This article was produced with AI assistance and reviewed by an editor. For further details, please refer to our Terms and Conditions.